Screener
Avalo Therapeutics AVTX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Common stock—$0.001 par value; 200,000,000 shares authorized at June 30, 2026 and December 31, 2025; 52,900,692 and 18,512,757 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 53 | 18 |
| Series C Preferred Stock—$0.001 par value; 4,085 and 34,326 shares of Series C Preferred Stock authorized at June 30, 2026 and December 31, 2025, respectively; 4,085 and 18,792 shares of Series C Preferred Stock issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Series C-1 Preferred Stock—$0.001 par value; 4,295 and 0 shares of Series C-1 Preferred Stock authorized at June 30, 2026 and December 31, 2025, respectively; 4,295 and 0 shares of Series C-1 Preferred Stock issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 953,700 | 531,485 |
| Accumulated other comprehensive (loss) income | (583) | 68 |
| Accumulated deficit | (504,510) | (448,522) |
| Total stockholders’ equity | 448,660 | 83,049 |
| Total liabilities, mezzanine equity and stockholders’ equity | $490,783 | $116,458 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's total liabilities & equity?
- Avalo Therapeutics (AVTX) reported total liabilities & equity of $490.78M in Q2 2026.
- How has Avalo Therapeutics's total liabilities & equity changed year-over-year?
- Avalo Therapeutics's total liabilities & equity increased by 287.7% year-over-year, from $126.58M to $490.78M.
- What is the long-term trend for Avalo Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Avalo Therapeutics's total liabilities & equity has grown at a 21.6% compound annual growth rate (CAGR), from $43.76M to $116.46M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Avalo Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude